Company intelligence / Profile preview

Replicon Health

Espoo, Uusimaa, Finland

Ownership: Private
Development stage: Other

Overview

Replicon Health has developed a new chemical entity (RH013001) showing efficacy in activating aerobic energy metabolism, with successful healthy human trials demonstrating reduced low-grade inflammation and rapid immune adaptation; preliminary placebo-controlled clinical study hit main therapeutic targets and confirmed mechanism, with further development toward a major, confidential "blockbuster" indication targeting large unmet medical need[1].

Therapeutic areas: ImmunologyInfectious DiseasesMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

RH013001

Unknown

Beyond the preview

Go deeper on Replicon Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Replicon Health.

Explore the full profile